Hospira Recalls Fentanyl Citrate Inj Due to Defective Vials

Hospira stated the potential risk of patient harm is deemed low since the defective vials are readily available
Hospira stated the potential risk of patient harm is deemed low since the defective vials are readily available

Hospira announced a voluntary recall of 3 lots of Fentanyl Citrate Injection 50mcg/mL due to confirmed ampules with broken tips. 

The affected products contain Lot #59277EV (Exp 1Nov2017), #60028EV (Exp 1Dec2017), and #60082EV (Exp 1Dec2017). They are supplied as 10 ampule per tray and 100 ampules per case. Hospira stated the potential risk of patient harm is deemed low since the defective vials are readily identifiable.  

Related Articles

Fentanyl Citrate Injection, an opioid, is indicated as short-term analgesia during anesthetic periods, premedication, induction and maintenance; and in the immediate postoperative periods as need arises; as an analgesic supplement in general or regional anesthesia; concomitantly with neuroleptic (eg, droperidol) as an anesthetic premedication, for anesthesia induction and as an adjunct in the maintenance of general and regional anesthesia; and as an anesthetic in combination with oxygen in selected high risk patients (eg, undergoing open heart surgery, complicated neurological or orthopedic procedures). Fentanyl Citrate is used for intravenous (IV) or intramuscular (IM) use.

Distributors should further notify those who may have received the recalled product. 

For more information call (877) 946-7747 or visit Hospira.com.

Loading links....